Singapore, Singapore

Takahiro Kamiya

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2024-2025

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Takahiro Kamiya: Innovator in Therapeutic Immune Cell Enhancement

Introduction

Takahiro Kamiya is a prominent inventor based in Singapore, known for his significant contributions to the field of therapeutic immune cells. With a total of three patents to his name, he has made remarkable strides in enhancing the efficacy of immune responses against cancer.

Latest Patents

Kamiya's latest patents focus on innovative methods for enhancing the efficacy of therapeutic immune cells. One of his notable inventions involves the use of a receptor, such as a chimeric antigen receptor (CAR), which activates an immune response upon binding to a cancer cell ligand. This method is used in conjunction with a target-binding molecule that aims to remove or neutralize specific proteins or molecules, ultimately generating enhanced anti-cancer immune cells. The invention also encompasses engineered immune cells that exhibit improved therapeutic efficacy and their various applications.

Career Highlights

Takahiro Kamiya is affiliated with the National University of Singapore, where he continues to advance research in immunotherapy. His work has garnered attention for its potential to revolutionize cancer treatment through innovative approaches to immune cell engineering.

Collaborations

Kamiya collaborates with Dario Campana, a fellow researcher, to further explore the applications of their findings in therapeutic settings.

Conclusion

Takahiro Kamiya's contributions to the field of therapeutic immune cells highlight his innovative spirit and dedication to improving cancer treatment. His patents reflect a commitment to advancing medical science and enhancing patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…